Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
United Food and Commercial v. Pfizer, Inc.
Case Number:
17-1333
Court:
Nature of Suit:
Companies
Sectors & Industries:
-
December 07, 2017
4th Circ. Frees Pfizer From Antitrust Suit Over Celebrex Patent
The Fourth Circuit on Thursday granted an unopposed motion to dismiss an antitrust suit brought against Pfizer Inc. by a putative class of health benefits plans that alleged the company used anti-competitive practices to get a patent for the inflammation medication Celebrex.
-
October 04, 2017
End Payors Urge 4th Circ. To Revive Celebrex Antitrust Suit
A potential class of health benefit plans told the Fourth Circuit on Tuesday that they're allowed to sue Pfizer Inc. over the tactics it allegedly used to get a patent for the inflammation medication Celebrex, as even though they're indirect purchasers, their states have an exception allowing them to bring antitrust suits.